
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934**

April 15, 2002

(Date of earliest event reported)

MEDICAL DISCOVERIES, INC.

(Exact name of registrant as specified in its charter)

Utah

0-12627

87-0407858

(State or other jurisdiction of
incorporation or organization)

(Commission File No.)

(I.R.S. Employer
Identification No.)

738 Aspenwood Lane
Twin Falls, Idaho 83301
(208) 736-1799

(Address of principal executive offices and telephone number, including area code)

TABLE OF CONTENTS

[Item 9. Regulation FD Disclosure](#)

[SIGNATURES](#)

[INDEX OF EXHIBITS](#)

[EXHIBIT 99](#)

Item 9. Regulation FD Disclosure

This Current Report on Form 8-K is filed for the purpose of disclosing the press release that was released on April 15, 2002 and is attached hereto as Exhibit 99.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MEDICAL DISCOVERIES, INC.

/s/ Judy Robinett

Judy Robinett
Chief Executive Officer

Date: April 15, 2002

INDEX OF EXHIBITS

Number	Description
99	Press Release issued April 15, 2002

CONTACT:
Judy Robinett 208-736-1799

FOR IMMEDIATE RELEASE

SALT LAKE CITY, Utah, April 15, 2002 — AIDS is the most devastating disease humankind has faced, according to a recent United Nations report. Medical Discoveries, Inc. (MDI) plans to utilize its proprietary products in the worldwide battle to successfully treat this deadly disease. Today, MDI is well positioned to launch FDA-approved testing and proceed toward U.S. product introductions and foreign licensing agreements. Let me share a brief overview. You may also find more information at www.medicaldiscoveries.com.

Medical Discoveries, Inc. is a publicly traded bio-pharmaceutical research company (Over The Counter, Bulletin Board as MLSC), engaged in the research, development and validation of a new class of drugs based upon the company's patented and proprietary electrolysis technologies. MDI is developing active anti-viral (HIV/AIDS), anti-bacterial and anti-fungal agents for a variety of human applications.

We have developed a product called MDI-P, a compound produced by the electrolysis of saline using a patented instrument with proprietary electrodes. MDI holds eight U.S. patents and two Japanese patents on its core technologies, comprising intellectual property spanning more than a decade of work from around the globe. We will continue to aggressively develop foreign patent protection while safeguarding our technologies and expert information.

MDI also intends to file an Investigational New Drug (IND) application with the Food & Drug Administration (FDA). Upon FDA acceptance and approval, we will undertake Human Clinical Trials, Phases 1 and 2, involving patients infected with the AIDS virus.

Our team is passionate about MDI and committed to achieving success. Thank you for your time and support. You can contact me directly at judy@medicaldiscoveries.com.

Best Regards,

Judy M. Robinett
President & Chief Executive Officer

* * * * *

Information in this press release relating to the potential of MDI constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties, including but not limited to: MDI's lack of significant operating revenue to date; MDI's need for substantial and immediate additional capital; the fact that MDI may dilute existing shareholders through additional stock issuances; the extensive governmental regulation to which MDI is subject; the fact that MDI's technologies remain unproven; the intense competition MDI faces from other companies and other products; and MDI's reliance upon potentially inadequate intellectual property. Additional information about these and other factors that could affect MDI's business is set forth in MDI's 2001 Annual Report on Form 10-KSB and other filings with the Securities and Exchange Commission.

###